ABSCI CORP Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
ABSCI CORP (ABSI) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $25.77 million as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2023-11-14
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $25.77M.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $48.55M.
- 2023-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $54.01M.
- 2022-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $61.84M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2023-09-30 | $25.77M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $48.55M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $54.01M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $61.84M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |